About Gastrin-releasing peptide receptor
Gastrin-releasing peptide receptor (GRPR) is a protein
from Homo sapiens identified by UniProt accession
P30550, 384 residues long.
MolForge cross-references it against 0 known binders and
155 disease associations.
Target properties
| Protein name | Gastrin-releasing peptide receptor |
|---|
| UniProt accession | P30550 |
|---|
| Gene | GRPR |
|---|
| Organism | Homo sapiens |
|---|
| Length | 384 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (155)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.27
- ovarian cancer · score 0.26
- breast adenocarcinoma · score 0.25
- head and neck squamous cell carcinoma · score 0.17
- low grade glioma · score 0.14
- neoplasm · score 0.11
- neuroblastoma · score 0.10
- breast cancer · score 0.09
- pachyonychia congenita · score 0.09
- cancer · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P30550-F1 | alphafold | PREDICTED | 78.52 | — |
Amino-acid sequence (384 residues)
MALNDCFLLN LEVDHFMHCN ISSHSADLPV NDDWSHPGIL YVIPAVYGVI ILIGLIGNIT LIKIFCTVKS MRNVPNLFIS SLALGDLLLL ITCAPVDASR YLADRWLFGR IGCKLIPFIQ LTSVGVSVFT LTALSADRYK AIVRPMDIQA SHALMKICLK AAFIWIISML LAIPEAVFSD LHPFHEESTN QTFISCAPYP HSNELHPKIH SMASFLVFYV IPLSIISVYY YFIAKNLIQS AYNLPVEGNI HVKKQIESRK RLAKTVLVFV GLFAFCWLPN HVIYLYRSYH YSEVDTSMLH FVTSICARLL AFTNSCVNPF ALYLLSKSFR KQFNTQLLCC QPGLIIRSHS TGRSTTCMTS LKSTNPSVAT FSLINGNICH ERYV
Explore Gastrin-releasing peptide receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets